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Purpose: Neoadjuvant chemotherapy (NACT) and
radical surgery (RS) have emerged as a possible alter-
native to conventional radiation therapy (RT) in locally
advanced cervical carcinoma. In 1990, a phase III trial
was undertaken to verify such a hypothesis in terms of
survival and treatment-related morbidity.
Patients and Methods: Patients with squamous cell,
International Federation of Gynecology and Obstetrics
stage IB2 to III cervical cancer were eligible for the
study. They received cisplatin-based NACT followed by
RS (type III to V radical hysterectomy plus systematic
pelvic lymphadenectomy) (arm A) or external-beam RT
(45 to 50 Gy) followed by brachyradiotherapy (20 to 30
Gy) (arm B).
Results: Of 441 patients randomly assigned to
NACTRS or RT, eligibility was confirmed in 210 and
199 patients, respectively. Treatment was adminis-
tered according to protocol in 76% of arm A patients
and 72% of arm B patients. Adjuvant treatment was
delivered in 48 operated patients (29%). There was no
evidence for any significant excess of severe morbidity
in one of the two arms. The 5-year overall survival (OS)
and progression-free survival (PFS) rates were 58.9%
and 55.4% for arm A and 44.5% and 41.3% for arm B
(P  .007 and P  .02), respectively. Subgroup survival
analysis shows OS and PFS rates of 64.7% and 59.7%
(stage IB2-IIB, NACTRS), 46.4% and 46.7% (stage
IB2-IIB, RT) (P  .005 andP  .02), 41.6% and 41.9%
(stage III, NCATRS), 36.7% and 36.4% (stage III, RT)
(P  .36 and P  .29), respectively. Treatment had a
significant impact on OS and PFS.
Conclusion: Although significant only for the stage
IB2 to IIB group, a survival benefit seems to be associ-
ated with the NACTRS compared with conventional RT.
J Clin Oncol 20:179-188. © 2001 by American
Society of Clinical Oncology.
SURVIVAL OF WOMEN with locally advanced cervi-cal cancer has remained substantially unchanged dur-
ing the last two decades. The long-term outlook is grim,
with overall 5-year survival rates of approximately 40%
when conventional treatments are used.1-4 Neoadjuvant
chemotherapy (NACT) followed by radical surgery (RS)
has emerged as a valid alternative for investigation. The
main objectives of preoperative chemotherapy are the po-
tential elimination of micrometastases and shrinkage of the
primary tumor bulk to achieve radical operability. Encour-
aging results were reported from different pilot studies that
used this approach.5-17 In particular, a 48% to 100%
operability rate was observed after NACT with no influence
on surgery-related morbidity, pathologically confirmed
complete responses were detected in 9% to 18%, and the
incidence of lymph node metastases was much lower than
expected for the same stage and tumor size.5-17 More
important, the observed 5-year survival rates (83% and 45%
for the stage IB2 to IIB and III groups, respectively)
strongly suggested a cure benefit from NACT when it was
followed by RS compared with exclusive radiation therapy
(RT).4,12-14 On the other hand, in the early 1990s, prelimi-
nary data from randomized trials on NACT preceding RT
did not show any survival advantage with respect to RT
alone.18,19 Therefore, based on the above considerations, an
Italian multicenter randomized trial was undertaken in 1990
to compare the efficacy and toxicity of sequential NACT
and RS versus exclusive RT, taken as standard treatment, in
patients with locally advanced cervical carcinoma.
PATIENTS AND METHODS
Patients aged less than 70 years with untreated, locally advanced
(International Federation of Gynecology and Obstetrics [FIGO] stage
IB2 to III) squamous cell carcinoma of the uterine cervix were eligible.
Criteria for exclusion were Eastern Cooperative Oncology Group
performance status greater than 2, severe systemic disease, other
malignancy (except for adequately treated basal cell carcinoma),
pre-existing peripheral neuropathy and/or hearing loss, inadequate bone
marrow reserve (WBC  4,000/mm3 and/or platelet count  100,000/
mm3), and abnormal hepatic (serum bilirubin  1.5 mg/dL) and renal
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(creatinine clearance  60 mL/min and/or serum creatinine  1.2
mg/100 mL) functions. The clinical staging procedure was performed
according to the system adopted by FIGO.20 Abdominal and pelvic
computed tomography or magnetic resonance imaging was also in-
cluded in the staging work-up; abdominal lymphangiography was
optionally performed. Informed consent was to be obtained from the
patients. The study was examined and approved by the ethical
committees in each participating center.
Treatment Plan
Patients were randomized to either NACT followed by RS or
exclusive RT. The study design is detailed in Fig 1. The NACT
regimen was not predetermined, but minimal requirements were a
cisplatin-containing regimen with a  240 mg/m2 total cisplatin dose
with a maximum of two additional drugs, administered over a period of
6 to 8 weeks. After NACT, the patients were clinically reassessed and
classified as suitable or unsuitable for RS. The latter patients were
treated by RT. RS consisted of radical hysterectomy (type III to V)21
plus systematic (at least 20 nodes to be resected) pelvic lymphadenec-
tomy (aortic lymphadenectomy was optional). Postoperative RT was
given in patients with positive surgical resection margins and/or
metastatic nodes. In the case of node metastasis, the choice of adjuvant
treatment was based on the institution’s policy (ie, chemotherapy,
external-beam RT, or no further therapy).
Conventional treatment consisted of external-beam, megavoltage RT
(45 to 50 Gy) to the whole pelvis over 5 to 6 weeks. In the presence of
metastatic pelvic nodes, detected by computed tomography/magnetic
resonance imaging or lymphangiography, an extra dose of 5 to 7 Gy
was administered. Intracavitary low-dose-rate brachytherapy (20 to 30
Gy to the tumor volume) was provided 2 to 4 weeks after external RT.
According to International Commission on Radiation Unit report 38,22
the dose was prescribed to tumor volume, without a fixed minimum
dose at point A. Aortic node metastases, when present, were irradiated
(45 Gy/5 weeks, followed by a 5-Gy boost to residual disease
eventually detected) with extended fields encompassing pelvic and
aortic volume or at the end pelvic irradiation, in the case of a pelvic
complete remission. Salvage treatments were allowed in patients who
showed progressing disease.
NACT-induced toxicity was evaluated according to World Health
Organization criteria,23 and surgery and RT-related morbidities were
classified using the French-Italian glossary of complications.24 Patients
were followed up 1 month after completion of treatment, every 3
months for the first 2 years, and at 6-month intervals thereafter. Local
and distant failures were defined as disease recurring inside and outside
the true pelvis (including aortic nodes), respectively. All case report
forms were reviewed first by two study members and further verified by
two independent investigators (one radiotherapist and one surgeon).
Randomization and Statistical Considerations
Patients were randomly assigned to NACT&RS or RT by telephon-
ing the trial data center. They were stratified at randomization by
disease stage (IB2 to IIA  4cm; IIB; III), age ( 60 years;  60
years), and institution.
The main end point of the study was (overall and progression-free)
survival. Sample size (400 patients) and a minimum follow-up of 2
years were planned to detect a 20% difference in outcome between the
two arms (with a power of 80% at a significance level of 5%). Patient
characteristics were compared by 2 test. Survival curves were com-
puted using the method of Kaplan and Meier,25 and the differences
were compared by the log-rank test. The main statistical analysis was
done by intention to treat. Survival comparisons were also done for all
eligible patients and for those receiving treatment according to the
protocol. Cox’s proportional-hazards regression model was used to
adjust for possible prognostic factors.26
RESULTS
Patients
Between January 1990 and July 1996, 441 patients were
randomized from 14 Italian centers. Most of the patients
(371, 84%) were from the six main participating institu-
tions. Thirty-two (7%) of the randomly assigned patients
were ineligible to participate further (17 NACT&RS pa-
tients, 15 RT patients) (Fig 2). Therefore, a total of 409
eligible patients received treatment as assigned (210
NACT&RS patients, 199 RT patients). The baseline char-
acteristics of eligible patients show no statistically signifi-
cant differences between the two arms (Table 1).
Delivery of Planned Treatment
The analysis of treatment revealed that 58 (25.5%) and 55
patients (28%) in the NACT&RS and RT arms, respec-
tively, had protocol deviations (Fig 2). In particular, 2% of
randomized patients received no treatment and 6% under-
went alternative treatment, while assigned treatment was
Fig 1. Study design. Abbreviations: RS, radical surgery; CR, complete
response; SRM /, surgical resection margins negative/positive; N /,
lymph node–negative/positive; RT, radiotherapy; CT, chemotherapy.
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inadequate for 49 (23%) and 33 patients (16.5%) in the
NACT&RS and RT arms, respectively. In the NACT&RS
arm, the reasons for inadequate treatment were as follows:
more than 20% cisplatin total dose reduction (one patient)
or more than 2-week delay of NACT administration (11
patients), in the absence of toxicity; selective ( 20 nodes
resected) pelvic lymphadenectomy; and type II radical
hysterectomy (40 patients) (more than one reason present in
three patients). In the RT arm, the reasons were that a less
than 60-Gy total dose (point A) was delivered in 21 patients
and that in 18 patients the total treatment time was  90
days (more than one violation present in six patients).
Chemotherapy
The following chemotherapy regimens were used: (1)
cisplatin and bleomycin (cisplatin 80 mg/m2 on days 1 and
2; bleomycin 15 mg/m2 on days 1 and 8) every 3 weeks for
two courses (96 patients, 48%); (2) cisplatin, vincristine,
and bleomycin (cisplatin 50 mg/m2, vincristine 1 mg/m2,
and bleomycin 30 mg over 24 hours) for six weekly courses
(66 patients, 33%); (3) cisplatin and ifosfamide (cisplatin 43
mg/m2 and ifosfamide 3.5 mg/m2 only on cycles 1, 4, and 7)
for seven weekly courses (20 patients, 10%); and (4)
single-agent cisplatin (at 40 mg/m2) for six weekly courses
(19 patients, 9%). The median cisplatin total dose adminis-
tered was 300 mg/m2 (range, 150 to 320 mg/m2), and the
median duration of NACT was 39 days (range, 16 to 56 days).
Due to toxicity, NACT was discontinued in 11 cases
(5%), delayed (from 1 to 2 weeks) in 30 cases (15%), and
dose-reduced in seven cases (3%). Treatment-affecting
toxicity mainly consisted of moderate to severe myelotox-
icity (grade 2 to 4 leukopenia or thrombocytopenia and/or
grade 3 anemia; 87%) and mild to severe (transient)
nephrotoxicity (6%). Cardiotoxicity (transient grade 3 ar-
rhythmia) and hepatotoxicity (grade 3 AST elevation) were
the causes of chemotherapy discontinuation in two patients;
these two patients subsequently underwent RT.
Surgery
One hundred sixty-four patients (78%) were operated on,
37 (18%) were judged not amenable for RS, and nine
patients (4%) received a completely different or no treat-
ment and were excluded from this analysis. In particular, 26
patients (13%) showed stable (7%) or progressive disease
(6%) at clinical reassessment, and two patients (1%) were
shifted to exclusive RT due to chemotherapy-related toxic-
ity; also, in nine patients (4%), RS was abandoned at
Fig 2. Trial profile.
Table 1. Characteristics of the Patients
Characteristic
Arm A (n  210) Arm B (n  199)
No. % No. %
Age, years
Median 49 52
Range 25-70 28-69
Performance status
0 197 94 181 91
1-2 13 6 18 9
FIGO stage
IB2 to IIA  4 cm 87 41 87 44
IIB 72 35 76 38
III 51 24 36 18
Tumor size  5 cm 113 54 115 58
WHO grade
1-2 133 63 123 62
3 71 34 65 32
Ungraded 6 3 11 6
Lymph node status
Negative 145 69 148 74
Positive 49 23 43 22
Positive aortic 11 5 7 3
Unknown 16 8 8 4
Abbreviation: WHO, World Health Organization.
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laparotomy (due to intraperitoneal or perilymph node dis-
ease spread, pelvic fibrosis, or unresectable primary tumor).
Type III to IV radical hysterectomy was performed in 150
patients (91%) and type V in four patients (2%), while 10
patients (5%) underwent type II radical hysterectomy based
on the decision of the treating physician. Systematic pelvic
lymphadenectomy was performed in 130 patients (79%),
with a median number of nodes resected of 36 (range, 20 to
81). Thirty-four patients (21%) underwent selective pelvic
lymphadenectomy (median, 14 nodes; range, six to 19
nodes), and 77 patients (47%) underwent aortic lymphade-
nectomy (median, 18 nodes; range, one to 42 nodes), on the
basis of the decision of the treating surgeon.
Pathologic examination of the surgical specimens re-
vealed no residual cervical tumor in 22 cases (13%) and
microinvasive disease only in a further 13 (8%). There was
no evidence of significant differences among the various
regimens used with respect to induction of pathologic
response (data not shown). Parametrial and vaginal speci-
mens were positive in 38 (23%) and 32 cases (19.5%),
respectively. Pelvic and aortic lymph nodes were involved
in 48 (29%) and four patients (2%), respectively, with no
cases of isolated aortic metastasis. In particular, 10 meta-
static nodes (34%) were found in the 29 operated patients
with positive nodes at the staging work-up. On the other
hand, 35 patients (29%) with clinically negative lymph
nodes had positive results at pathologic examination.
Extracervical disease (parametria, n  2; vagina, n 
3; nodes, n  4) was detected in seven (20%) of the 35
patients who showed no frankly invasive tumor in the
cervical specimen.
Surgical resection margins were positive in 11 patients
(7%), four of whom also showed metastatic nodes. There-
fore, a total of 55 patients were eligible for adjuvant
treatment (Fig 3). Based on the protocol rules, this consisted
of external RT (n  38) or chemotherapy (n  10);
moreover, seven (16%) of the 44 patients with node
metastasis (and negative surgical resection margins) re-
ceived no further treatment.
RT
After external-beam RT to the whole pelvis, intracavitary
RT was used in all but 50 patients (28%), because of
anatomic reasons (32%), tumor progression (18%), severe
toxicity (6%), patient refusal (6%), or noncompliance
(38%). These patients completed treatment by external
radiation extradose. The median total dose delivered to
point A was 70 Gy (range, 10.5 to 105 Gy) (Fig 4). In
particular, patients who underwent external RT only and
external RT followed by brachytherapy received a median
total dose of 61.1 Gy (range, 10.5 to 76.8 Gy) and 71.3 Gy
(range, 44 to 105 Gy), respectively. Overall, the median
time of radiation treatment delivery was 62 days (range, 11
to 135 days). In particular, 44% of patients required less
than 8 weeks, and 27% required more than 100 weeks. For
patients who completed treatment with curative intent, the
median total dose at point A was 71 Gy (range, 60 to 105
Gy), with a median total duration of therapy of 58 days
(range, 33 to 87 days). Two of seven patients initially
diagnosed as having metastatic aortic nodes were eligible
for and underwent extended-field radiation. Compliance
with the planned radiation schedule was relatively accept-
able, with 72% of patients receiving treatment according to
the protocol. Discontinuation of therapy due to toxicity
occurred only in one patient (0.6%) and was due to
progressive disease in nine patients (5%). Pelvic control was
achieved in 99 patients, ie, 50% of the eligible patients.
Treatment-Related Morbidity
Both treatments were well tolerated, and no treatment-
related deaths were reported. Table 2 summarizes the severe
morbidity of the two treatments. Overall, severe (Chassagne
Fig 3. Postoperative management. Abbreviations: CR, complete re-
sponse; SRM /, surgical resection margins negative/positive; N /,
lymph node–negative/positive; Ext. RT, external radiotherapy; CT.
chemotherapy.
Fig 4. RT: correlation between dose and time. All patients allocated to the
RT are included.
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grade 2 to 3) complications affected 52 (32%) and 49
patients (28%) in the chemosurgery and radiotherapy arms,
respectively. Moreover, a 27% severe (World Health Orga-
nization grade 3 to 4) additional toxicity was considered for
the NACT group (see also Chemotherapy, above). Short-
term (within 30 days from the end of treatment) severe
complications affected 25 patients (15%) undergoing sur-
gery. In particular, there were no intraoperative severe
complications; however, accidental injuries to vessels, re-
quiring additional blood transfusion(s), occurred in nine
cases (5%). Bladder dysfunction (17%) and lymphocysts
(18%) were the most frequent postoperative complications,
but they were severe only in three (2%) and 13 cases (8%),
respectively. Less frequent short-term severe complications
were abdominal wound dehiscence (2%), ureteral stenosis/
fistula (1%), rectovaginal fistula (1%), small bowel infarc-
tion (0.6%), and transient leg paresis (0.6%). RT-induced
short-term severe toxicity occurred in nine patients (5%).
Adverse effects consisted mainly of acute proctitis/cystitis
(8%), but they were rarely (2%) severe. Other effects were
diarrhea (1%), symptomatic cutaneus edema (1%), myelo-
depression (0.6%), and uterine perforation (0.6%) requiring
treatment discontinuation.
Long-term severe complications occurred in 32 patients
(19.5%) from the NACT arm. Dyspareunia affected 10% of
patients and represented the most frequent late complica-
tion, followed by chronic neurologic bladder (7%), vesico-,
ureteral-, or rectovaginal fistulas (3%), laparocele (3%),
persistent lymphocysts (2%), and chronic cystitis (1%). Late
severe morbidity of RT was observed in 39 patients (22%),
consisting mainly of vaginal stenosis/dyspareunia (16%).
Less frequent complications were hydronephrosis (2.2%),
pelvic fibrosis (1.6%), enterovaginal fistula (1%), chronic
cystitis (0.6%), bowel occlusion (1%), malabsorption
(0.6%), and fecal incontinence (0.5%).
The relative risk of long-term severe complications for
chemosurgery versus RT alone was 0.86 (95% confidence
interval [CI], 0.49 to 1.50). Moreover, it is to be considered
that 38 (23%) of the patients operated on underwent
adjuvant radiotherapy and that 30% of these patients will
present with late severe complications.
Survival
Survival analysis was done on an intention-to-treat basis
on all 441 randomized patients (227 NACT&RS patients,
214 RT patients). Moreover, separate analyses were con-
ducted on the 409 eligible patients (210 NACT&RS pa-
tients, 199 RT patients) and on the 295 patients receiving
treatment according to the protocol (152 NACT&RS pa-
tients, 143 RT patients).
The median possible duration of participation in the study
was 79 months (range, 42 to 120 months). The median
follow-up of the overall population was 40 months (range,
1 to 107 months). When the analysis was restricted to
surviving patients, the median duration of follow-up was 53
months (range, 3 to 107 months). Eight patients (2%) were
lost to follow-up, and 21 (5%) died of intercurrent disease.
In the intention-to-treat analysis, the 5-year overall sur-
vival rates for patients undergoing NACT&RS and RT were
56.5% (95% CI, 49.2% to 63.7%) and 44.4% (95% CI,
36.4% to 52.4%), respectively (P  .01). The approximate
10% survival increase for patients in the NACT arm was
confirmed by the analysis of eligible patients: 58.9% (95%
CI, 51.4% to 66.3%) v 44.5% (95% CI, 36.3% to 52.7%) (P
 .007). This difference was also observed when the
analysis was restricted to patients receiving treatment ac-
cording to the protocol: 60.2% (95% CI, 51.8% to 68.6%) v
46.8% (95% CI, 37.4% to 56.2%) (P  .02) (Fig 5).
Progression-free survival analyses showed approximately
the same differences between the two arms: 55.4% (95% CI,
47.9% to 62.8%) v 41.3% (95% CI, 31.7% to 50.9%) (P 
.02) for the eligible patients, and 56.9% (95% CI, 48.5% to
65.3%) v 47.8% (95% CI, 39.2% to 56.4%) (P  .03) for
those treated according to the protocol (Fig 6).
The 5-year survival analyses by FIGO stage again
showed significantly longer overall survival (64.7% [95%
CI, 56.5% to 72.9%] v 46.4% [95% CI, 37.2% to 55.6%],
P  .005) and progression-free survival (59.7% [95% CI,
51.3% to 68.1%] v 46.7% [95% CI, 38.1% to 55.3%], P 
.02) for the stage IB2 to IIB patients in the NACT arm
compared with the RT arm, respectively (Fig 7). Separate
analyses by stage subgroup confirmed the significant differ-
ences in overall survival (68.9% [95% CI, 56.9% to 81.3%]
v 50.7% [95% CI, 38.8% to 63.2%], P  .01) and
Table 2. Severe Morbidity by Treatment Arm
Toxicity
NACT (n  201) RS (n  164) RT (n  177)
No. of
Events %
No. of
Events %
No. of
Events %
Gastrointestinal 52 26 4 2 10 6
Urinary 3 1 23 14 6 3
Cardiovascular 1* 0.5 16 10 — —
Hematopoietic 49 24 — — 1 0.6
Cutaneous 75† 37 8 5 5 3
Peripheral nerve symptoms 1 0.5 1 0.6 — —
Vaginal — — 16 10 29 16
Total patients 55 27 52 32 49 28
NOTE. NACT severe (grade 3 or 4) induced toxicity was evaluated
according to WHO criteria; other severe (grade 2 or 3) toxicities were graded
according to the French-Italian Glossary of Complications. Some patients had
more than one complication.
*Transient cardiac arrhythmia.
†Hair loss.
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progression-free survival (65.4% [95% CI, 55.1% to 75.2%
v 50.6% [95% CI, 40.4% to 60.3%], P  .01) for stage IB2
to IIA more than 4 cm but not for stage IIB (overall
survival: 58.6% [95% CI, 46.3% to 60.3% v 42%, 95% CI,
28.4% to 56.5%, P .15; progression-free survival: 53.2%,
95% CI, 40.8% to 65.4% v 42.8%, 95% CI, 29.1% to 57.2%,
P  .51). Survival rates for the stage III patients did not
significantly differ in the two arms (overall survival: 41.6%
[95% CI, 26.5% to 56.7%] v 36.7% [95% CI, 19.6% to
53.7%], P .36; progression-free survival: 41.9% [95% CI,
27.4% to 56.4%] v 36.4% [95% CI, 20.1% to 52.7%], P 
.29) (Fig 8).
The results of univariate and multivariate analyses are
shown in Table 3 and 4. Significant variables in both overall
and progression-free survival analyses were FIGO stage,
cervical tumor diameter, lymph node status at computed
tomography/lymphangiography, and treatment delivered. In
particular, the relative risks of overall and progression-free
survival for NACT&RS versus RT were 0.63 (95% CI, 0.47
to 0.86) and 0.67 (95% CI, 0.49 to 0.90), respectively.
Overall, 184 patients (45%) developed progressive dis-
ease: 84 (40%) in the chemosurgery arm and 100 (50%) in
the RT arm. Of these patients, 153 (83%) died of disease,
whereas seven (8%) and three (3%) in the NACT and RT
arms, respectively, were rescued by salvage treatments. As
far as the pattern of progression is concerned, a distant
component was present in 59 cases (32%): 31 (37%) and 28
(28%) in the NACT and RT arms, respectively. These
differences were not statistically significant. In patients
whose treatment was completed according to the protocol,
Fig 5. Overall survival of (A) all randomized patients, (B) eligible
patients, and (C) patients treated according to the protocol.
Fig 6. Progression-free survival of (A) eligible patients and (B) patients
treated according to the protocol.
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81.5% of pelvic progressions and 76% of distant progres-
sions developed within 2 years from the end of primary
therapy. Timing by pattern of progression did not signifi-
cantly differ between the two arms.
DISCUSSION
In our study, we found that sequential NACT and RS was
more effective than exclusive RT in the cure of locally
advanced squamous cell cervical cancer. At 5 years, there
was a 10% to 15% survival advantage for patients in the
experimental arm included in the intention-to-treat analysis
(P  .01). The statistically significant difference was
confirmed by separate analyses conducted on eligible pa-
tients (P .007) and on those receiving treatment according
to the protocol (P  .02). The progression-free survival
analyses still confirmed such a therapeutic advantage. Che-
motherapy-induced tumor shrinkage rendered radical exci-
sion possible in a high percentage of cases, and longer
overall and progression-free survival rates were observed in
the chemosurgery arm. Although there was increased, but
reversible, hematologic toxicity due to chemotherapy, the
incidence of long-term complications was similar in the two
treatment groups.
The positive impact of sequential NACT&RS on survival
was also supported by the results of multivariate analyses of
both overall and progression-free survival. In fact, treatment
delivered was included among variables significantly affect-
ing the clinical outcome.
Fig 7. Stage IB2 to IIB: (A) overall survival; (B) progression-free survival.
Fig 8. Stage III: (A) overall survival; (B) progression-free survival.
Table 3. Univariate and Multivariate Analyses of Overall Survival
Univariate P Multivariate P
Relative
Risk 95% CI
Treatment group
NACT  RS .01 .004 0.63 0.47-0.86
RT
FIGO stage
IB2 to IIB .005 .02 0.61 0.43-0.87
III
Age
 60 years NS NS — —
 60 years
Cervical tumor size
4 cm .0008 .008 0.66 0.47-0.90
 5 cm
Lymph node status*
Negative .0001 .001 0.53 0.38-0.74
Positive
*Lymph node status was assessed at the staging work-up by computed
tomography/magnetic resonance imaging or lymphangiography.
Abbreviations: CI, confidence interval; NS, not significant.
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The analysis of both overall and progression-free survival
by FIGO stage revealed a significant increase for stage IB2
to IIB, whereas only a statistical trend was detected for the
more advanced stage group. These data are in accordance
with our previous results suggesting that the more advanced
the stage, the more limited the benefit achievable by NACT
followed by surgery. This could be satisfactorily explained
by the direct correlations between disease volume, chemo-
responsiveness, radical operability, and outcome in many
solid tumors, including cervical cancer.6,14-17,27 The greater
the volume, the larger is the hypoxic and resting phases cell
population with reduced or no chemosensitivity and the
probability of developing resistant clones. The tumor extent,
however it is expressed (ie, FIGO stage, cervical tumor
size), is highly predictive of response, which, in turn,
significantly affects radical resectability and therapeutic
outcome.14-17 In fact, RS was feasible in 55% of stage III
patients compared with 85.5% of those presenting with a
less advanced stage (P  .0001). Moreover, the evaluation
of surgical specimens from radically operated patients
revealed a higher incidence of persistent tumor in the
parametria and lymph nodes for stage III (50%) compared
with stage IB2 to IIB (37%).
About one third of failures showed a distant component.
Interestingly, there was no statistically significant difference
between the two arms with regard to the pattern of disease
recurrence. These data are in accordance with those reported
by the Argentine group28-30 and suggest that the relatively
short duration of NACT may be not enough to sterilize
distant micrometastases.
Overall, given the multicenter study setting, treatment
compliance was acceptable, with approximately 75% of
treatments delivered according to the protocol. In the
NACT&RS arm, violations mostly concerned surgery
(19%) rather than chemotherapy (6%) and were due to
inadequate surgical excision of primary tumor and/or lymph
nodes. With respect to RT, inadequacy of treatment was
generally due to variation in the dose (11%) and/or time of
delivery (9%). A median total dose at point A of 70 Gy
(range, 10.5 to 105 Gy) delivered in 62 days (range, 11 to
135 days) seems to be lower than that considered optimal
RT in advanced cervical cancer. In this setting, 80 to 90 Gy
are now considered adequate doses at point A to be
delivered over a limited treatment time.31 Moreover, the
inability to apply intracavitary radiation in 28% of these
patients because of anatomic reasons was disappointing.
However, survival results achieved by exclusive RT in the
present study (5-year progression-free survival, 41.3%)
seem to be comparable to those recently reported (40%)
from a randomized trial with higher average doses delivered
to point A (89 Gy; median duration, 58 days).32 In the
present trial, the incidence of clinically detectable aortic
metastasis was less than 5%, although it is known that no
imaging technique is capable of detecting microscopic
aortic metastasis. On the other hand, the role of prophy-
lactic extended-field radiation is still controversial. This
is why extended-field radiation was reserved only for
patients with evident aortic metastasis who achieved
pelvic complete remission.
Nearly all phase II and phase III trials have demonstrated
the feasibility of the combination of NACT with both RT or
surgery.6-17,28-30,33-37,39 In the present study, there was no
statistical evidence for an excess of severe complications in
one of the two arms, although approximately 30% of severe
transient—mostly hematologic—toxicity is to be further
considered for the NACT group. Severe morbidity is,
however, associated with both treatment strategies in ap-
proximately 30% of cases. In particular, the addition of RT
in about one fourth of radically operated patients may have
affected long-term morbidity, with uncertainty about its
therapeutic value. Overall, no treatment-related deaths were
reported, and the most severe late complications, such as
vaginal stenosis/dyspareunia, chronic neurologic bladder,
and vaginal fistulas, occurred in less than 20% of patients.
Most of the randomized studies investigating the role of
NACT compared the combination of NACT and RT with
RT alone, with no evidence of a significant survival benefit
by the addition of NACT.36 The cross-resistance between
platinum-based chemotherapy and radiation has been sug-
gested as one of the explanatory mechanisms of such a
phenomenon40 However, the lack of improvement, or even
Table 4. Univariate and Multivariate Analyses of Progression-Free
Survival
Univariate P Multivariate P
Relative
Risk 95% CI
Treatment group
NACT  RS .02 .008 0.67 0.49-0.90
RT
FIGO stage
IB2 to IIB .004 .02 0.63 0.45-0.89
III
Age
 60 years NS NS — —
 60 years
Cervical tumor size
4 cm .009 .05 0.74 0.54-1.00
 5 cm
Lymph node status*
Negative .0001 .008 0.54 0.39-0.76
Positive
*Lymph node status was assessed at the staging work-up by computed
tomography/magnetic resonance imaging or lymphangiography.
186 BENEDETTI-PANICI ET AL
2012 from 130.192.105.57
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on October 31,
Copyright © 2002 American Society of Clinical Oncology. All rights reserved.
worsening, in survival in the presence of substantial
clinical response leaves room for other hypotheses in-
volving possible changes in tumor cell kinetics induced
by upfront chemotherapy.
On the other hand, the removal of residual disease after
tumor shrinkage induced by chemotherapy may overcome
cell kinetics–based changes resulting in the lack of disease
control by RT. Although such a strategy seemed to be
associated with improved outcomes on the basis of phase II
studies,5-17 few randomized trials have investigated the use
of NACT followed by RS. At the time of this writing, only
two randomized trials have been published28-30,38,39; an-
other one is still in progress (Gynecologic Oncology Group
study 141). To our knowledge, our study is the first
European phase III trial for which mature data are reported.
Nevertheless, the national dimension of the study must be
taken into the account; the results may be limited to Italy. In
the Argentine trials, the chemosurgical sequence always
resulted in the most efficacious treatment in terms of
survival for stage IB2, IIB, and IIIB disease when compared
with surgery alone, with chemotherapy followed by radia-
tion or exclusive RT.28-30,37 However, contrary to the
current trial, postoperative external-beam radiation was
always included in these trials’ designs. In our study, in fact,
adjuvant RT was given according to the protocol only to
23% of the entire operated group. In particular, it was given
to 21% and to 32% of stage IB2 to IIB and stage III patients,
respectively. While the use of adjuvant RT in the less
advanced stage subgroup remains of uncertain value, the
routine addition of RT performed in the Argentine trials
may be advantageous for a better local control in the more
advanced stage subset. This might explain the higher
survival rate (63%) reported by Sardi et al30 for the stage
IIIB patients treated with NACT&RS followed by RT
compared with our results (42%), which were almost
superimposable with those achieved by exclusive RT
(37%). Strategies involving integrated therapy, particularly
with regard to concurrent chemoradiation, have been inves-
tigated recently. In this respect, data are now available from
large randomized trials in favor of the concurrent use of
chemotherapy and RT in a spectrum of advanced disease
ranging from stage IB2 through stage IVA.32,41,42 The
addition of chemotherapy significantly increased the rate of
pelvic control and, consequently, patient survival, indicat-
ing that such an integrated treatment is the likely new gold
standard in the treatment of locally advanced disease.
Promising results have also been generated within our group
with regard to concurrent chemoradiation in a phase II
setting.43 Therefore, based on this evidence and on the data
from the present study, a new, prospective, randomized,
innovative trial comparing NACT and RS with chemora-
diotherapy seems to be worthwhile.
APPENDIX
The appendix is available online at www.jco.org.
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